InterCure (INCR.TA) Akcija Kursas
InterCure Kursas
Per pastaruosius 19 metus InterCure pajamos augo 14,3 % kasmet ir pasiekė 238,85 mln. ILS. Pelnas akcijai mažėjo 24,6 % per metus per pastaruosius 10 metus. InterCure grynoji marža −28,4 % yra išaugo palyginti su −57,2 % prieš kelerius metus. InterCure 12 mėn. konsensuso tikslinė kaina yra 7,14 ILS, apie žemiau kursą 44,2 %. Iš 7 analitikų 6 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
InterCure akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
InterCure akcija ir akcijų analizė
Dažnai užduodami klausimai apie InterCure akciją
InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.
InterCure Ltd is primarily active in the medical cannabis industry.
The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.
InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.
InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.
InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.
InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.
Analitikai šiuo metu nustato vidutinę InterCure akcijos tikslinę kainą 7,14 ILS (mediana: 7,14 ILS), t. y. −44,2 % palyginti su paskutine kaina. Konsensusas pagrįstas 7 analitikų reitingais.
7 analitikai šiuo metu vertina InterCure akciją: 6 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad InterCure gaus 574,00 mln. ILS pajamų ir 1,70 ILS pelno akcijai.
Pagal dabartinį kursą InterCure akcija kainuoja 3,61 EUR (12,80 ILS).
InterCure akcija (INCR.TA) kotiruojama 2 biržose, įskaitant: NASDAQ (INCR).
InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.
tikėtina pelnas InterCure yra 574,00 mln. ILS. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas InterCure yra 78,13 mln. ILS. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) InterCure šiuo metu yra 7,51. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti InterCure akcijos vertę.
Kainų ir pardavimų santykis (KUV) InterCure šiuo metu yra 1,02. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra InterCure akcijos įvertinimo metrika.
Eulerpool kokybės balas InterCure yra 2/10.
InterCure ISIN yra IL0011063760. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
InterCure WKN yra A1CZA8. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
InterCure prekybos žymė yra INCR.TA. Ši biržos žymė naudojama InterCure akcijoms prekiauti biržoje.
InterCure akcija
InterCure Pagrindiniai konkurentai
InterCure Biržos simbolis
InterCure FIGI
Visos InterCure pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė InterCure akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai InterCure. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: